Episode Details
Back to EpisodesCould personalized mRNA therapy be moving closer to clinical practice after positive phase 3 results in melanoma?
Episode 694
Published 1 month, 1 week ago
Description
This episode highlights three clinically relevant developments: positive phase 3 results for individualized mRNA neoantigen therapy plus pembrolizumab after melanoma surgery, emerging MRI and AI approaches that may identify Alzheimer’s-related brain changes years earlier, and substantial LDL-C treatment gaps under the 2026 ACC/AHA dyslipidemia guideline. Together, the findings underscore advances in precision oncology, early neurodegenerative risk detection, and cardiovascular prevention.